Phase II sbir
Ended Definitive Contract Awarded Last action
- Contract number
- W911QY17C0007
- Awardee
-
Cytosorbents Medical Inc. UEI LSF2KFUSY4K7
- Awarding agency
-
ACC Aberdeen Proving Ground
Army Contracting Command, Department of Defense
- Obligated
- $999,997
Award facts
- Contract value 100% obligated
- $999,996.59 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Funding agency
- Joint PEO Chemical and Biological Defense Acquisition Support Center, Department of Defense
- NAICS code
- 541712 Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
- PSC
- AJ11 General Science And Technology R&D Services; General Science And Technology; Basic Research
- Set-aside
- Total Small Business
- Competition
- Full and Open Competition after exclusion of sources · 1 offer Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Monmouth Junction, South Brunswick Township, NJ 08852, USA
- Research
- SBIR Program Phase II Action
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $0 | |
| Exercise an Option | $541,668 | |
| Other Administrative Action | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Original award | $458,328 |
About this award
This is a $999,996.59 firm-fixed-price Phase II SBIR contract awarded by the Joint PEO Chemical and Biological Defense to Cytosorbents Medical Inc., a small business manufacturer of medical devices and technologies. The contract is for research and prototype development services related to Cytosorbents' blood purification technologies, including an extracorporeal cytokine adsorber, a potassium adsorber, and a blood group antibody adsorber. These technologies are intended to treat critical care conditions such as septic shock and enable universal blood transfusions. The contract is set aside for small businesses and represents additional federal funding for Cytosorbents, which has also received research grants from the NIH and Army Medical Command to advance its medical device technologies.
Quick answers
Who was awarded contract W911QY17C0007?
W911QY17C0007 was awarded to Cytosorbents Medical Inc. by ACC Aberdeen Proving Ground (Army Contracting Command) on February 1, 2017.
How much is contract W911QY17C0007 worth?
The government has obligated $999,997 on W911QY17C0007.
Which agency awarded contract W911QY17C0007?
ACC Aberdeen Proving Ground (Army Contracting Command) awarded W911QY17C0007, with funding from Joint PEO Chemical and Biological Defense (Acquisition Support Center).
Was contract W911QY17C0007 competed?
The extent of competition for W911QY17C0007 was full and open competition after exclusion of sources. The government received 1 offer. It was set aside: Total Small Business.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award